Search

Search Constraints

You searched for: Is Part Of Cancer. Volume 124:Issue 2(2018)

Search Results

4. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation. Issue 2 (28th September 2017)

5. Clinical impact of colonization with multidrug‐resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia. Issue 2 (28th September 2017)

6. Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature. Issue 2 (28th September 2017)

10. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Issue 2 (6th December 2017)